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PRECLINICAL STUDIES
he Effect of Stem Cell
obilization by Granulocyte-Colony
timulating Factor on Neointimal Hyperplasia
nd Endothelial Healing After Vascular Injury
ith Bare-Metal Versus Paclitaxel-Eluting Stents
yun-Jai Cho, MD,*†‡ Tae-Youn Kim, BA,‡ Hyun-Ju Cho, MS,‡ Kyung-Woo Park, MD,*†‡
hu-Ying Zhang, MD,‡ Ji-Hyun Kim, MS,‡ Sung-Hwan Kim, MD,*†‡ Joo-Yong Hahn, MD,*†‡
yun-Jae Kang, MD,*†‡ Young-Bae Park, MD,*†‡ Hyo-Soo Kim, MD, PHD*†‡
eoul, Korea
OBJECTIVES The goal of this study was to investigate the effect of mobilized stem cells by granulocyte-
colony stimulating factor (G-CSF) on neointimal growth, the biologic impact on vascular
healing process, and the utility of paclitaxel-eluting stent (PES) in this circumstance.
BACKGROUND Questions have been raised on the safety of stem cell mobilization because of the tendency of
neointimal overgrowth in a recent clinical trial, despite improvement of cardiac function.
METHODS Rabbits underwent iliac artery injury with bare-metal stent (BMS) or PES and then received
rhG-CSF or placebo for 6 days. Morphometric analysis and scanning electron microscopy for
re-endothelialization were performed. The characteristics of mobilized peripheral blood
mononuclear cells were determined in vitro, and the fate of these cells was evaluated by
re-infusion with tagging in vivo.
RESULTS At day 60 after stenting, neointimal overgrowth was observed at BMS with G-CSF. The
tendency of neointimal overgrowth was substantially reduced on PES. Intriguingly,
the delayed endothelial recovery on PES was restored to normal after G-CSF treatment. The
G-CSF increased not only the endothelial progenitor cells, but also putative smooth muscle
progenitor cells. Paclitaxel, at working concentration, preferentially inhibited proliferation of
smooth muscle lineage cells rather than endothelial lineage cells.
CONCLUSIONS Our findings demonstrate that G-CSF mobilizes putative vascular progenitor cells in
peripheral blood, which induces neointimal overgrowth at stented vasculature. Unique
differential action of paclitaxel results in the enhanced endothelial healing with reduced
neointimal growth after G-CSF treatment, suggesting that drug-eluting stents might be the
optimal modality for revascularization in cytokine-based stem cell therapy. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.080Cardiol 2006;48:366–74) © 2006 by the American College of Cardiology Foundation
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whe strategy of mobilizing stem cells from the bone marrow
as initially contrived by hematologists to accelerate recov-
ry of the bone marrow after cancer chemotherapy and to
arvest hematopoietic stem cells from the peripheral blood
or bone marrow transplantation (1,2).
See page 375
n a recent experimental study, stem cells mobilized from
he bone marrow were shown to improve cardiac function
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050082 [Dr. H-S Kim]) and Stem Cell Research Center (SC 13122 [Dr. Y-B
ark]), Korea.G
Manuscript received October 24, 2005; revised manuscript received December 2,
005, accepted December 13, 2005.fter myocardial infarction (3). In patients with coronary
rtery disease, it was shown that, despite reduced basal
umber and function of endothelial progenitor cells (EPCs)
ompared with healthy control subjects, granulocyte-colony
timulating factor (G-CSF) administration mobilized pro-
enitor cells to the circulation and augmented EPC colony-
ormation (4). In a first-in-man trial (5), we reported that
ntracoronary infusion of peripheral blood stem cells mobi-
ized by G-CSF after coronary stenting of culprit lesions
ith a bare-metal stent (BMS) improved systolic function
nd myocardial perfusion without significant systemic in-
ammation in patients with myocardial infarction. Unex-
ectedly, we observed the tendency of G-CSF to potentially
romote neointimal growth at BMS. Our report and con-
ern from other investigators (6) have raised questions on
he safety of cytokine-induced mobilization. However, ow-
ng to the small number of patients enrolled in our study, it
as difficult to come to a conclusion on the effects of
-CSF on neointimal formation and restenosis at BMS.
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July 18, 2006:366–74 Mobilization and Vascular Injuryurthermore, there have not been studies to evaluate the
ffect of G-CSF on neointimal growth or to elucidate
ossible mechanisms.
The principal cause of in-stent restenosis is neointimal
yperplasia caused by excessive proliferation and accumula-
ion of vascular smooth muscle cells (SMCs) that arise from
ither the injured resident vascular tissue (7) or the bone
arrow (8,9). In the clinical field, drug-eluting stents have
hown efficacy in reducing neointimal hyperplasia through
nhibition of SMCs and have mostly replaced BMS in
ractice (10). However, little is known about the biologic
ffect of mobilized stem cells on the vascular healing process
fter paclitaxel-eluting stent (PES) implantation.
Therefore, in the present study, we investigated whether
-CSF–induced stem cell mobilization from the bone
arrow might have the potential to aggravate BMS neoin-
imal hyperplasia and whether this can be reduced by PES
n an animal model. Next, to elucidate its mechanism, we
tudied the characteristics of the mobilized cells and inves-
igated whether these cells incorporate into the injured
essels leading to neointimal overgrowth. We also studied
Abbreviations and Acronyms
BMS  bare-metal stent
BrdU  bromodeoxyuridine
EC  endothelial cell
ELISA  enzyme-linked immunosorbent assay
EPC  endothelial progenitor cell
G-CSF  granulocyte-colony stimulating factor
PDGF  platelet-derived growth factor
PES  paclitaxel-eluting stent
SEM  scanning electron microscopy
SMA  smooth muscle actin
SMC  (vascular) smooth muscle cell
SPC  smooth muscle progenitor cell
VEGF  vascular endothelial growth factor
VPC  vascular progenitor cell
igure 1. Schematic diagram of study design and end points. (A) Experi
reatment on neointimal growth or vascular healing of stented artery. (B) E
ncorporation into injured artery. BMS  bare-metal stent; d  day; PES  phe mechanism for the enhanced endothelial healing with
educed neointimal overgrowth at PES after stem cell
obilization by G-CSF.
ETHODS
nimal care and vascular injury. All animal experiments
ere performed after receiving approval from the Institu-
ional Animal Care and Use Committee (IACUC) of the
linical Research Institute in Seoul National University
ospital and complied with the National Research Coun-
il’s Guidelines for the Care and Use of Laboratory Animals
revised 1996).
Schematic diagram of study design and end points are
llustrated in Figure 1.
Male New Zealand White rabbits (3 to 3.5 kg; Yonam
aboratory Animals, Cheonan, Korea) received a 1% cho-
esterol diet from at least 2 weeks prior to vascular injury.
otal cholesterol levels were measured before injury. For
eripheral blood analysis and cell culture, eight rabbits
eceived either G-CSF (daily 70 g subcutaneously,
ong-A Pharmaceutical, Korea) or placebo (human albu-
in) for 6 days.
To determine whether the cells mobilized by G-CSF
ctually incorporate into the injured vessels, mononuclear
ells were isolated from a rabbit that received either G-CSF
r placebo, tagged with DiI (Molecular Probes, Eugene,
regon), and infused via arterial sheath into a recipient
abbit that received a balloon injury as previously described
11). Balloon injury was performed on bilateral iliac arteries
ith a 3.0 mm  20 mm balloon. At 14 days after balloon
njury with systemic cell infusion, rabbits were killed and
heir iliac arteries were harvested.
To evaluate re-endothelialization and neointimal hyper-
lasia after stenting, we deployed 20 BMS and 20 PES in
he right and left iliac arteries, respectively, in 20 rabbits
n  20, each stent) (BMS  EXPRESS, 2.75 mm  16
s to analyze the effect of granulocyte-colony stimulating factor (G-CSF)ment
xperiments to analyze the progenitor cell mobilization by G-CSF and
aclitaxel-eluting stent.
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Mobilization and Vascular Injury July 18, 2006:366–74m, Boston Scientific, Natick, Massachusetts; PES 
AXUS, 2.75 mm  16 mm, Boston Scientific) One day
fter stenting, rabbits were randomized to receive either
ecombinant human G-CSF (n  10) or placebo (n  10)
or 6 days. At day 30, selected stents were dissected
ongitudinally to evaluate luminal surface as en-face, fixed in
lutaraldehyde, and processed for scanning electron micros-
opy (SEM) for evaluation of re-endothelialization (n  3
ach for four groups, BMS vs. PES in G-CSF vs. placebo).
e previously validated that SEM and traditional immuno-
istochemical staining with endothelial cell marker CD31,
ECAM-1 is well correlated in terms of re-endothelialization
11). At day 60 (n  7 each for four groups, BMS vs. PES
n G-CSF vs. placebo), stents were fixed in 10% buffered
ormalin with perfusion fixation. Plastic embedded sections
ere stained with hematoxylin and eosin, and the degree of
eointimal growth was analyzed. Morphometric analysis
as performed with a computerized digital image-analysis
ystem (Image Pro version 4.5, MediaCybernetics, Silver
pring, Maryland).
ell culture and immunocytochemical staining. All ex-
eriments dealing with humans or human products were
onducted with informed consent and approved by the
nstitutional review board of Seoul National University
ospital.
UMAN EPCS. Peripheral blood (50 cc) was obtained from
ealthy donors with informed consent. The mononuclear
ells fraction was collected and cultured as previously de-
cribed (12). Isolated mononuclear cells were resuspended in
GM-2 BulletKit system (EGM-2 MV, Clonetics, San
iego, California) consisting of endothelial basal medium,
uman epidermal growth factor, vascular endothelial
rowth factor (VEGF), human fibroblast growth factor-
asic with heparin, insulin-like growth factor-1, ascorbic
cid, heparin, and 5% fetal bovine serum.
UMAN ARTERIAL ENDOTHELIAL CELLS (ECS) AND VASCU-
AR SMOOTH MUSCLE CELLS (SMCS). Human right gastro-
piploic arteries were obtained from gastrectomy specimens
ith informed consent. The ECs and SMCs were isolated
nd cultured (12). The ECs were grown in the same media
s EPCs, and SMCs were cultured in DMEM (GIBCO,
rand Island, New York) containing 10% fetal bovine
erum.
ABBIT PERIPHERAL BLOOD-ORIGINATED CELLS. Peripheral
lood (70 cc) mononuclear cells were isolated by
istopaque-1077 (Sigma, St. Louis, Missouri) density gra-
ient centrifugation and resuspended in EGM-2 MV. Cells
ere subsequently cultured in either EGM-2 MV to induce
nd maintain endothelial phenotype or EGM-2 supple-
ented with 10% fetal bovine serum and platelet-derived
rowth factor (PDGF)-BB stimulation (10 ng/ml, R&D
ystems, Minneapolis, Minnesota) to facilitate vascular
mooth muscle phenotype. After 3 weeks in culture, mor-
hological appearance and immunocytochemical staining
ere used to define phenotypes. To detect endothelial vhenotype, we used primary antibodies against CD31
DAKO, Carpinteria, California), which were detected
ith PE-labeled goat anti-mouse IgG, and antibodies
gainst alpha-smooth muscle actin (SMA) (FITC-
onjugated, Sigma) were used to detect SMCs.
low cytometry. Antigen analysis was performed on both
eripheral blood mononuclear cells and cultured cells from
abbits treated with G-CSF or placebo. Single cell suspen-
ions were analyzed on a FACSCalibur flow cytometer
Becton Dickinson, Franklin Lakes, New Jersey). The
ITC-conjugated anti–alpha-SMA (Abcam, Cambridge,
nited Kingdom), VE-Cadherin (BD PharMingen, San
iego, California), and CD31 (DAKO) with secondary
etection with PE-conjugated immunoglobulin were used.
sotype-matched IgG was used as a control.
ell proliferation assay. The EPCs, ECs, and SMCs (1
04 cells) were seeded to each well of a 96-well plate with a
nal volume of 200 l/well conditioned medium. To assess
he anti-proliferative effects of paclitaxel (Bristol-Myers
quibb, New York, New York) on human vascular cells and
obilized cells at various doses (0.1 nmol/l to 1000 mol/l),
he proliferative activities of each cell type were assessed by
nzyme-linked immunosorbent assays (ELISAs) for bro-
odeoxyuridine (BrdU) incorporation (Roche Diagnos-
ics, Mannheim, Germany) after 24 and 72 hours as
reviously described (13).
tatistical analysis. All data are presented as mean  SD.
ontinuous variables were compared by using the Student
test, and multiple comparisons were performed by analysis
f variance (ANOVA) with Bonferroni’s correction using
PSS version 11.0 (SPSS Inc., Chicago, Illinois). A p value
f 0.05 was considered statistically significant.
ESULTS
ffects of G-CSF on neointimal hyperplasia after stenting.
efore vascular injury, serum total cholesterol levels were
imilar between the G-CSF and placebo groups after 2
eeks of 1% cholesterol diet (910  272 mg/dl vs. 1,097
68 mg/dl, p  0.05). At day 60 after stenting of BMS or
ES at iliac arteries, the rabbits were killed and neointimal
rowth was analyzed (Fig. 2). Morphometric analysis (Figs.
C and 2D; n  7 each for four groups, by ANOVA with
onferroni’s correction) showed that neointimal formation
t BMS in the iliac artery of rabbits who received G-CSF
as greater than that of rabbits who received placebo
neointimal thickness: 0.26 0.04 mm vs. 0.34 0.04 mm
or BMS with placebo vs. BMS with G-CSF, p 0.015, n
). As expected, PES (0.14  0.05 mm) in the rabbits that
eceived placebo showed reduced neointimal growth com-
ared with BMS (0.26  0.04 mm) in the rabbits that
eceived placebo (PES with placebo vs. BMS with placebo,
 0.001). In the rabbits where stem cells were mobilized
y G-CSF, there was still a tendency of neointimal over-
rowth even at PES, which was not statistically significant.
0.14 0.05 mm vs. 0.19 0.04 mm for PES with placebo
s. PES with G-CSF, p  0.36).
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July 18, 2006:366–74 Mobilization and Vascular InjuryIn terms of efficacy, the neointimal formation at PES
ven after G-CSF was significantly smaller than that at
MS after placebo (neointimal thickness: 0.19  0.04 mm
s. 0.26  0.04 mm, p  0.036; neointimal area: 1.62 
.21 mm2 vs. 2.05  0.25 mm2 for PES with G-CSF vs.
MS with placebo, p  0.015).
obilization of putative vascular progenitor cells by
-CSF and in vitro differentiation to SMC or EC. After
days of G-CSF injection, total white blood cells signifi-
antly increased in the G-CSF group compared with pla-
ebo (total white blood cell count: 36,900  22,328/l vs.
,114  1,401/l for G-CSF vs. placebo, p  0.01). There
as no significant difference in the number of red blood cells
nd platelets between the two groups (data not shown).
Peripheral mononuclear cells were isolated for flow cy-
ometry and serial cultures (Fig. 3). Granulocyte-colony
timulating factor increased not only the endothelial pro-
enitor cells (CD31, VE-Cadherin, CD34, KDR)
ut also the fraction of double-positive cells for VE-
adherin/alpha-SMA or CD31/alpha-SMA, sug-
esting increased mobilization of putative vascular progen-
igure 2. Effects of stem cell mobilization by G-CSF on neointimal hyperp
f the iliac artery 60 days after BMS and PES deployment with or without s
ggravated neointimal formation at BMS. The trend of such aggravation o
t PES even after G-CSF treatment was less than that at BMS after plac
albumin); PES, in the placebo group; G-BMS, BMS in the G-CSF group
f neointimal thickness was presented as mean  SD BMS versus PES, p
nd PES versus G-PES, p  0.36. (D) Neointimal area: BMS versus PES
nd PES versus G-PES, p  0.505 by analysis of variance with Bonferrotor cells (VPCs). In serial cultures of the mobilized (eripheral mononuclear cells, immunocytochemical staining
howed that the cells mobilized by G-CSF gave rise to both
ndothelial and smooth muscle lineage cells. After 21 days
f culture with specific factors, VEGF stimulation induced
hese cells mainly to endothelial lineage cells (cobble stone
hape and CD31), whereas PDGF induced a part of them
o smooth muscle lineage cells (“hill and valley” [14]
orphology and alpha-SMA) in addition to double-
ositive cells (CD31/alpha-SMA) or endothelial lin-
age cells.
ncorporation of mobilized peripheral mononuclear cells
nto neointima and differentiation to SMC. Peripheral
lood from a rabbit that received either G-CSF or placebo
or 6 days was collected. Isolated mononuclear cells (final
solated cell number was 1  108) were then tagged with
iI and infused systemically after balloon injury (Fig. 4).
he segment of injured artery was harvested 14 days later.
n the rabbits receiving peripheral blood mononuclear cells
not mobilized by G-CSF but treated with placebo), the
nfused cells were scantily observed in the media and they
id not express the smooth muscle phenotype, alpha-SMA
fter stenting, BMS: EXPRESS versus PES: TAXUS. (A and B) Histology
ell mobilization by G-CSF. Stem cell mobilization by G-CSF significantly
intimal formation was also observed at PES. Note that neointimal growth
Arrowheads indicate internal elastic lamina; BMS, in the placebo group
ES, PES in the G-CSF group. (C) Digital image-analyzed morphometry
.001; BMS versus G-BMS, p  0.015; BMS versus G-PES, p  0.036;
0.001; BMS versus G-BMS, p  0.053; BMS versus G-PES, p  0.015;
rrection. Abbreviations as in Figure 1.lasia a
tem c
f neo
ebo.
; G-P
 0Fig. 4A). This result suggests that peripheral blood mono-
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Mobilization and Vascular Injury July 18, 2006:366–74uclear cells at normal status do not have substantial
umbers of VPCs that incorporate into neointima and
ifferentiate to vascular SMC. However, in the rabbits
eceiving the mobilized mononuclear cells by G-CSF, the
iI positive, infused mononuclear cells, were observed in
oth the media (Fig. 4B) and the neointima (Fig. 4C), some
xpressing the smooth muscle phenotype, alpha-SMA, and
ome not expressing it (Fig. 4D). These findings suggest
hat at least a portion of the cells mobilized by G-CSF
ncorporated into both the media and neointima, differen-
iated into SMCs, and participated in neointimal growth.
ifferential inhibitory effect of paclitaxel on proliferation
f smooth muscle versus endothelial lineage cells. To
lucidate the mechanism for the maintained inhibition of
eointimal formation at PES even after stem cell mobiliza-
ion by G-CSF, we studied the effect of paclitaxel on the
roliferation of mobilized rabbit EPCs, rabbit smooth
uscle progenitor cells (SPC), human EPCs, and human
ascular cells with ELISA to measure BrdU incorporation
Fig. 5). In a dose-dependent manner, paclitaxel preferen-
ially inhibited rabbit SPCs and human SMCs proliferation
ompared with rabbit and human EPCs as well as human
C. At the presumable concentration of paclitaxel at the
ascular tissue deployed with PES (100 nmol/l to 1 mol/l,
resented by Boston Scientific), proliferation of rabbit SPCs
nd human SMCs were inhibited even at a lower concen-
ration (100 nmol/l), whereas rabbit EPCs and human
PCs and ECs were not. Only a higher concentration of
aclitaxel (1 mol/l) decreased the proliferative activity of
uman ECs, whereas that of EPCs was maintained. In
ther words, the proliferation of EPCs from both rabbit and
uman samples were not affected at these low and high
orking concentrations of paclitaxel in contrast to SPCs,
igure 3. Mobilization of putative vascular progenitor cells by granulocyte-c
uscle cell (SMC) or endothelial cell (EC). Four quadrant analysis of anti
-CSF or placebo injection, and serial observation of cell culture with
PDGF). Endothelial lineage cells were identified by CD31 and VE-Cadh
taining (red color), and vascular smooth muscle lineage cells were
ITC-alpha-SMA immunostaining (green color). Both endothelial and sm
uring culture of peripheral blood mononuclear cells, endothelial lineage
he cells to differentiate into smooth muscle lineage in addition to doubleMCs, and ECs. wffects of G-CSF on re-endothelialization of PES. Ob-
erving the inhibitory effect of paclitaxel at a high working
oncentration on endothelial proliferation in vitro, we eval-
ated the pattern of endothelial recovery after PES deploy-
ent in vivo by comparing with that after BMS.
We evaluated re-endothelialization at BMS and PES by
ross and scanning electron microscopy (SEM) at day 28, a
elatively early time point (Fig. 6, n  3 each for four
roups). The BMS showed complete re-endothelialization
n the placebo as well as G-CSF administered groups. The
ES in rabbits receiving placebo, however, showed tissue
emorrhage around stent struts in gross examination (Fig.
A). The delayed endothelial recovery was confirmed in
hese samples by SEM of the luminal surface of arteries
Fig. 6B). The denuded area was approximately 10% of
uminal surface, especially around the stent struts, where
igh tissue concentration of paclitaxel permeates into the
issue. However, PES in rabbits receiving G-CSF, which
ould mobilize EPCs, showed accelerated endothelial heal-
ng without hemorrhage around stent struts or denuded
urface.
ISCUSSION
he administration of G-CSF might have the potential to
romote neointimal growth in the setting of vascular injury;
owever, the mechanism of such effects remains unclear.
ere, we showed that G-CSF mobilizes not only endothe-
ial progenitor cells but also putative VPCs to the peripheral
lood, which could incorporate into neointima and differ-
ntiate to SMC, leading to neointimal overgrowth at BMS.
uch a trend of cytokine-induced neointimal overgrowth
as also observed at PES, but the magnitude of neointimal
vergrowth was reduced by PES, which might be associated
stimulating factor (G-CSF) and in vitro differentiation to vascular smooth
xpression in circulating peripheral blood mononuclear cells after 6 days of
lar endothelial growth factor (VEGF) or platelet-derived growth factor
E-CAD) in FACS analysis and PE-labeled-CD31 immunocytochemical
tified by alpha-smooth muscle actin (SMA) in FACS analysis and
muscle lineage cells increased with G-CSF treatment in peripheral blood.
ncreased preferentially with VEGF. In contrast, PDGF induced a part of
ive (CD31/alpha-SMA) or endothelial lineage cells.olony
gen e
vascu
erin (V
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oothith inhibition of smooth muscle lineage cell proliferation
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July 18, 2006:366–74 Mobilization and Vascular Injuryy paclitaxel. In terms of efficacy, the neointimal area at
ES even after G-CSF treatment was still smaller than that
t BMS after placebo. Under usual circumstances without
tem cell mobilization, re-endothelialization at PES, espe-
ially near stent struts, was significantly delayed because
aclitaxel at high working concentrations (especially near
tent struts) inhibits the proliferation not only of SMC but
lso of EC. Stem cell mobilization with G-CSF, however,
ignificantly accelerated endothelial recovery at PES. Such a
nique finding was corroborated by the in vitro experiment,
here paclitaxel preferentially inhibited the proliferation of
mooth muscle lineage cells rather than endothelial lineage
uch as EPC.
utative VPCs in injured artery. It has been generally
elieved that neointimal SMCs originate locally from the
edial layer of the injured artery (7). But this traditional
igure 4. Incorporation of mobilized peripheral mononuclear cells into vas
lood mononuclear cells were isolated from rabbit after 6 days of granulocy
red color). In another rabbit, these cells were infused systemically after ball
ith alpha-smooth muscle actin (SMA) (green color). Peripheral blood m
DiI/alpha-SMA) cells, implying that the infused cells did not different
ononuclear cells from G-CSF–injected animals were observed as DiI/
mplying that the cells mobilized by G-CSF incorporated into vascular w
eointima but did not differentiate into SMC (D). Such infiltration of th
hickness at 2 weeks (B, C, and D) compared with control animals infuseoncept has been challenged by new evidence demonstrating ather sources of SMCs in injured arteries (8,9). Recently, it
as been reported in embryo (15), bone marrow (16), and
eripheral blood (14) that putative VPCs might give rise to
MC. Our results support this new concept that the bone
arrow might have the potential to give rise to VPCs and
hese progenitor cells might participate in vascular repair
nd lesion formation after injury. This study demonstrates
or the first time that G-CSF could mobilize VPCs into the
eripheral circulation and that these cells contribute to
esion growth as well as healing after vessel injury.
tem cell mobilization and neointimal growth. Regard-
ng restenosis, there are conflicting data and many contro-
ersies on the effect of stem cell mobilization, in both animal
tudies and human clinical trials. In a rat carotid balloon
njury model with G-CSF, neointimal thickness was re-
arkably reduced by 60% (17). Previously, we reported, in
wall and differentiation to vascular smooth muscle cell (SMC). Peripheral
lony stimulating factor (G-CSF) or placebo injection and tagged with DiI
jury to the iliac artery. Two weeks after injury, frozen sections were stained
uclear cells from placebo-injected animals (A) revealed no double-positive
SMC but remained as mono-macrophage lineage cells. But the mobilized
-SMA double positive cells within both media (B) and neointima (C),
d differentiated to SMC. Some of the mobilized cells incorporated into
s mobilized by G-CSF into vascular wall led to the increased neointimal
h non-mobilized peripheral mononuclear cells (A).cular
te-co
oon in
onon
iate to
alpha
all anmodel of rabbit iliac artery balloon injury with intravas-
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Mobilization and Vascular Injury July 18, 2006:366–74ular radiation therapy (11), that GM-CSF did not aggravate
eointimal formation but accelerated re-endothelialization. In
hese two studies, the degrees or characteristics of vascular
njury are different from those in the present study that
valuated stented artery in hypercholesterolemic rabbits. The
at carotid injury model represents “endothelial denudation”
njury with simple and less atherogenic (“less SMC-
ependent”) milieu in rat species, and balloon injury with
ascular radiation therapy implies total “eradication of local
mooth muscle proliferative activity.” In other words, in
hese two animal models, the rapidity of endothelial recov-
ry rather than activity of SMC proliferation plays a pivotal
ole in determining neointimal formation.
In a clinical trial (5) and the present experimental study,
eointimal thickness with BMS stenting increased after
-CSF mobilization. In these two studies, the nature of
ascular injury is significantly different from that in previous
xperimental models. Coronary atherosclerotic lesions in
igure 5. Differential inhibitory effect of paclitaxel on proliferation of sm
aclitaxel on rabbit endothelial progenitor cells (EPCs) and smooth muscle
or bromodeoxyuridine (BrdU) incorporation. At the presumable tissue con
PC still maintained its proliferative potential, whereas SPCs did not. *E
ature endothelial cells (ECs), and vascular smooth muscle cells (SMCs) we
ven from a low therapeutic concentration (100 nmol/l). In contrast, E
oncentration. But proliferative activity of EPCs was not inhibited in the r
 0.001; †EPC versus EC, p  0.036; #EC versus SMC, p  0.002 batients are more complicated and rich in growth factors tnd cytokines stimulating SMC proliferation. Furthermore,
tent deployment under the situation of hypercholesterol-
mia significantly stimulates SMC proliferation, resulting in
eointimal formation at these lesions that are determined
ore by SMC rather than EC. Therefore, the cells mobi-
ized by G-CSF, which includes not only endothelial but
lso smooth muscle progenitor cells, lead to more SMC
roliferation than endothelial recovery, resulting in neoin-
imal overgrowth. Taken together, the effect of stem cell
obilization by cytokines on neointimal growth might be
ariable among various vascular injury models.
e-endothelialization of drug-eluting stent. Drug-
luting stents have been proven to be an effective therapeutic
odality to prevent restenosis and have mostly replaced
MS in real-world practice. Despite the excellent results of
ES in clinical trials (18), pathologic examinations of
nimal (19) and human (20) samples have shown that
elayed re-endothelialization might be an important dele-
muscle versus endothelial lineage cells. (A) Anti-proliferative effects of
nitor cells (SPCs) were evaluated by enzyme-linked immunosorbent assays
tion (100 nmol/l to 1 mol/l) of paclitaxel at vessel with TAXUS stenting,
rsus vascular progenitor cell, p  0.001; †p  0.002. (B) Human EPCs,
o evaluated. Paclitaxel caused a dose-dependent inhibition of SMC growth
owth was inhibited only at 1 mol/l of paclitaxel, a high therapeutic
f therapeutic concentration eluted from TAXUS stent. *EC versus SMC,
lysis of variance with Bonferroni’s correction.ooth
proge
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C grerious tissue reaction of PES (21). Experience from cyto-
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July 18, 2006:366–74 Mobilization and Vascular Injuryoxic intravascular radiation therapy (11,22) has shown that
elayed endothelial recovery aggravates vascular inflamma-
ion and leads to thrombosis and catch-up restenosis.
In this study, delayed endothelial recovery and tissue
emorrhage around stent struts were observed in PES. This
elayed endothelial recovery, however, was overcome by
-CSF–induced stem cell mobilization, which accelerated
he re-endothelialization of PES. To better understand the
ffects of paclitaxel on the various cells mobilized by
-CSF, we studied the effect of paclitaxel at the presumable
issue concentration where PES, TAXUS (Boston Scien-
ific) stent is deployed (100 nmol/l to 1 mol/l, presented by
oston Scientific). At these doses, proliferation of SMCs
as preferentially inhibited rather than ECs in a dose
ependent manner. Proliferative activity of ECs was inhib-
ted at the higher concentration (1 mol/l), but proliferation
f EPCs was not affected. Taken together, PES in the
igure 6. Effects of stem cell mobilization on endothelial recovery after
ndings (B) of stented rabbit iliac artery at 28 days. (First row) Endothel
eointimal growth by G-CSF–mediated stem cell mobilization was reflecte
trut silhouette on SEM. (Second row) In case of PES, the evidences of del
nding and uncovered stent struts in SEM finding. (Fourth row) After ste
obblestone-shaped endothelial cells without focal hemorrhage, suggesting
rrows  stent struts not covered by endothelium, owing to delayed re-enetting of G-CSF administration might inhibit SMC pro- piferation yet at the same time be re-endothelialized by
PCs mobilized from the bone marrow.
It should be noted that the present study and a recently
ublished article (23) that evaluated the effect of sirolimus
n progenitor cells without mobilizers and on wire-
ediated vascular injury in a mouse model both raise the
ossibility of impeded endothelial recovery with these com-
ercially available drug eluting stents. Intriguingly, siroli-
us showed similar inhibitory effects on both SPCs and
PCs (23), but paclitaxel showed a differential dose-related
ffect on SPCs and EPCs as well as mature SMCs and ECs.
his difference might be due to the characteristics of the
articular drug coated on the stent.
tudy limitations. There are several limitations to this
tudy. First, we tested neointimal growth and endothelial
ecovery after vascular injury in a rabbit iliac artery model.
his study was conducted with juvenile rabbits without
and PES stenting. Gross (A) and scanning electron microscopy (SEM)
nd neointima were fully formed after BMS. (Third row) Aggravation of
the decreased transparency of gross finding and the disappearance of stent
ndothelial healing was observed as hemorrhage around PES struts in gross
mobilization with G-CSF, however, endothelial layers were covered with
enhanced endothelial recovery even on PES (arrowheads  hemorrhage;
elialization). Other abbreviations as in Figure 1.BMS
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Mobilization and Vascular Injury July 18, 2006:366–74abbits received a high-cholesterol diet, the plaque is gen-
rally thin, non-calcified, and primarily confined to the
ntima with high lipid content. Despite limitations and
nability to predict efficacy in humans, the hypercholester-
lemic rabbit iliac artery injury model has been considered
n acceptable choice for proving critical hypotheses regard-
ng putative mechanism of action of vascular intervention
24).
Second, we used recombinant human G-CSF in this
tudy. Therefore, it remains to be clarified whether human-
irected G-CSF might be applicable to animal models such
s the rabbit model. Because the pharmacokinetics of the
-CSF in rabbits is largely unknown, the dosage and
njection interval of G-CSF were based on human data.
owever, in rabbits after 6 days of injection, total white
lood cells measured in peripheral blood increased signifi-
antly compared with placebo. This finding might reflect
he therapeutic efficacy of human-directed bone marrow
obilizing cytokines in experimental animal models.
Finally, it is conceivable that G-CSF could have a direct
ocal effect if impregnated in a stent or delivered locally besides
ystemic progenitor cell mobilization. The potential direct
ffect of G-CSF on vasculature needs further investigation.
onclusions. Granulocyte-colony stimulating factor mo-
ilization might contribute to neointimal growth as well as
ndothelial recovery through the recruitment of VPCs,
hich differentiate into both EC and SMC. Paclitaxel in
itro and PES in vivo (TAXUS stents) effectively inhibited
roliferation and accumulation of smooth muscle lineage
ells. At sites of high drug-elution, PES showed a potential
eleterious effect on re-endothelialization through interfer-
nce of EC growth, which was overcome by EPCs mobi-
ized by G-CSF. Our data suggest that the combination of
ES and stem cell mobilization might have complementary
ffects on each other, one modality covering up the pitfalls
f the other modality: DES suppressing neointimal over-
rowth while stem cell mobilization enhances endothelial
ecovery on DES. Therefore, drug-eluting stents might be
he optimal modality for revascularization in cytokine-based
tem cell therapy.
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